Skyrizi Side Effects

Generic name: risankizumab

Medically reviewed by Philip Thornton, DipPharm. Last updated on Mar 10, 2024.

Note: This document contains side effect information about risankizumab. Some dosage forms listed on this page may not apply to the brand name Skyrizi.

Applies to risankizumab: parenteral injection for iv infusion, parenteral injection for sub-q use.

Side effects include:

Adverse reactions (≥1%) in patients with plaque psoriasis and psoriatic arthritis: upper respiratory infection, headache, fatigue, injection site reaction, tinea infection.  

Adverse reactions (>3%) in patients receiving induction treatment for Crohn disease: upper respiratory infection, headache, arthralgia.  

Adverse reactions (>3%) in patients receiving maintenance treatment for Crohn disease: arthralgia, injection site reaction, abdominal pain, anemia, pyrexia, back pain, arthropathy, urinary tract infection.

For Healthcare Professionals

Applies to risankizumab: intravenous solution, subcutaneous kit, subcutaneous solution.

Gastrointestinal

Common (1% to 10%): Abdominal pain^[Ref]

Dermatologic

Common (1% to 10%): Tinea infections (e.g., tinea pedis, tinea cruris, body tinea, tinea versicolor, tinea manuum, tinea infection)

Uncommon (0.1% to 1%): Folliculitis, urticaria

Postmarketing: Eczema, rash^[Ref]

Hematologic

Common (1% to 10%): Anemia^[Ref]

Hypersensitivity

Hypersensitivity

Common (1% to 10%): Hypersensitivity reactions^[Ref]

Immunologic

Very common (10% or more): Immunogenicity (24%), infections (e.g., cellulitis, osteomyelitis, sepsis, herpes zoster) (22%)^[Ref]

Local

Common (1% to 10%): Injection site reactions (e.g., bruising, erythema, extravasation, hematoma, hemorrhage, infection, inflammation, irritation, pain, pruritus, reaction, swelling, warmth)^[Ref]

Musculoskeletal

Common (1% to 10%): Arthralgia, arthropathy, back pain^[Ref]

Nervous system

Common (1% to 10%): Headache (e.g., tension headache, sinus headache, cervicogenic headache)^[Ref]

Other

Common (1% to 10%): Fatigue, asthenia, pyrexia^[Ref]

Respiratory

Very common (10% or more): Upper respiratory infections (e.g., respiratory tract infection [viral, bacterial, unspecified], sinusitis [including acute], rhinitis, nasopharyngitis, pharyngitis [including viral], tonsillitis) (up to 13%)^[Ref]

Frequently asked questions

• What are monoclonal antibodies?
• What's the dosing schedule for Skyrizi?
• Does Skyrizi cause cancer?
• Can you drink alcohol while taking Skyrizi?
• Skyrizi vs Humira for plaque psoriasis - How do they compare?
• Is Skyrizi approved for treating psoriatic arthritis?
• Who makes Skyrizi and where is it made?
• Skyrizi vs Ilumya. What’s the difference?
• What are the new drugs for plaque psoriasis?

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.

Medical Disclaimer